Press Releases

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium...

Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of...

Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International...

Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m....

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe,...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This...

Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas....

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev®...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on...

Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and...

Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched,...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May...

The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter calendar year 2016 on Thursday, May 12, 2016 at approximately 6:00 a.m. (ET)....

Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International,...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's...

Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on June 14, 2016 to shareholders of record on May 27, 2016.

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of John T. Hendrickson...

Perrigo Company plc (NYSE: PRGO; TASE) today released the following statement regarding recent media coverage concerning Chairman and CEO Joseph C. Papa: "We are aware of the speculation regarding...

Perrigo Company plc (NYSE: PRGO; TASE) today announced the first-to-market launch of the over-the-counter (OTC) store brand equivalent to Glucerna® aseptic adult nutritional shake for people with...

Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store brand equivalent to Mucinex®...

Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: SENTRY® Vantaguard™ 2 and SENTRY® Flea & Tick Collar...

Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: PetArmor® Advanced 2 and PetArmor® Flea & Tick Collar...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Barclays Global Healthcare Conference at 10:15 AM EST on Tuesday, March 15, 2016...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the previously...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance Unlimited...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Cowen Annual Healthcare Conference at 4:00 PM EST on Monday, March 7, 2016 at the...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the RBC Capital Markets Global Healthcare Conference at 8:00 AM EST on Wednesday,...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international...

Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's Chairman and CEO Joseph C. Papa commented, "The team...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on March 15, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will announce financial results for its calendar year and fourth quarter 2015 on Thursday, February 18, 2016 at approximately 6:00...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A®...

Perrigo Company plc (NYSE: PRGO; TASE) announced today that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail...

Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from the Company's October 22, 2015...

Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced the launch of combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release tablets to...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph Papa will present at the 34th Annual J.P. Morgan Healthcare Conference at 8:00 AM PST on Monday, January...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A® (tretinoin) from Matawan Pharmaceuticals,...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire Entocort® (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to the news that holders of a majority of its shares rejected Mylan's hostile tender offer, thereby expressing...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) issued the following response to Mylan's press release. Mylan is resorting to desperate tactics on the eve of its tender offer...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration ("FDA") approval for the generic version of...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today issued the following shareholder letter: November 9, 2015 CORPORATE GOVERNANCE, MYLAN STYLE: A QUESTION OF TRUST Dear...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to misleading statements regarding Marc Coucke, Perrigo Board member as well as Executive Committee member. In...